User login
Key clinical point: The rate of pathological complete response (pCR) was significantly higher in patients with early-stage breast cancer (BC) who received neoadjuvant treatment with pegylated liposomal doxorubicin-cyclophosphamide followed by docetaxel (LC-T) vs epirubicin-cyclophosphamide followed by docetaxel (EC-T).
Major finding: The pCR rate was significantly higher with LC-T vs EC-T in the overall cohort (25.3% vs 15.5%; P = .026) and in the subgroup of patients with triple-negative BC (47.1% vs 15.4%; P = .013).
Study details: Findings are from a retrospective study including 359 patients with stage I-III BC who received neoadjuvant treatment with LC-T (n = 178) or EC-T (n = 181) followed by surgery.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Tsai J-H et al. Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: A multicenter retrospective case-control study. Breast Cancer Res Treat. 2023 (Mar 4). Doi: 10.1007/s10549-023-06867-6
Key clinical point: The rate of pathological complete response (pCR) was significantly higher in patients with early-stage breast cancer (BC) who received neoadjuvant treatment with pegylated liposomal doxorubicin-cyclophosphamide followed by docetaxel (LC-T) vs epirubicin-cyclophosphamide followed by docetaxel (EC-T).
Major finding: The pCR rate was significantly higher with LC-T vs EC-T in the overall cohort (25.3% vs 15.5%; P = .026) and in the subgroup of patients with triple-negative BC (47.1% vs 15.4%; P = .013).
Study details: Findings are from a retrospective study including 359 patients with stage I-III BC who received neoadjuvant treatment with LC-T (n = 178) or EC-T (n = 181) followed by surgery.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Tsai J-H et al. Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: A multicenter retrospective case-control study. Breast Cancer Res Treat. 2023 (Mar 4). Doi: 10.1007/s10549-023-06867-6
Key clinical point: The rate of pathological complete response (pCR) was significantly higher in patients with early-stage breast cancer (BC) who received neoadjuvant treatment with pegylated liposomal doxorubicin-cyclophosphamide followed by docetaxel (LC-T) vs epirubicin-cyclophosphamide followed by docetaxel (EC-T).
Major finding: The pCR rate was significantly higher with LC-T vs EC-T in the overall cohort (25.3% vs 15.5%; P = .026) and in the subgroup of patients with triple-negative BC (47.1% vs 15.4%; P = .013).
Study details: Findings are from a retrospective study including 359 patients with stage I-III BC who received neoadjuvant treatment with LC-T (n = 178) or EC-T (n = 181) followed by surgery.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Tsai J-H et al. Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: A multicenter retrospective case-control study. Breast Cancer Res Treat. 2023 (Mar 4). Doi: 10.1007/s10549-023-06867-6